加入VIP免费下载招银国际-药明康德-603259-Growth momentum to accelerate in 2H22E-220728
文本预览：
药明康德(603259) Strong 1H22 results. WuXi AppTec reported 1H22 revenue of RMB17.8bn, up69% YoY (71%/66% YoY for 1Q/2Q22), attributable recurring net income ofRMB3.8bn, up 81% YoY (106%/65% YoY for 1Q/2Q22), and attributable adjustedNon-IFRS net income of RMB4.3bn, up 76% YoY (118%/49% YoY for 1Q/2Q22).Earnings are in line with our forecasts with 1H22 revenue / adjusted Non-IFRS netincome accounting for 46%/51%, respectively, of our 2022 full-year estimates.Revenue growth in 1H22 would have further accelerated by 7.2 ppts to 76% YoYand adjusted Non-IFRS GPM would have improved by 1.9 ppts YoY to 38.1%under constant currency exchange rates. The management increased its revenuegrowth guidance to 68-72% YoY from 65-70% YoY for 2022E, supported by itssolid RMB35bn backlog (+76% YoY) in 1H22. WuXi Chemistry delivered phenomenal growth despite COVID-19interruptions, driven by strong growth from both COVID and non-COVIDprojects. WuXi Chemistry revenue jumped by 102% YoY in 1H22, mainlydriven by the 145% YoY revenue growth of chemical CDMO services. Basedon our estimates, the Company booked ~RMB4.2bn revenue from commercialstage COVID-19 projects in 1H22, accounting for ~32% of WuXi Chemistryrevenue. Excluding the commercial-stage COVID-19 projects, the segmentrevenue still achieved robust growth of 37% YoY in 1H22, indicating asustainable demand from non-COVID-19 projects. Driven by the successfulone-stop CRDMO business model, we forecast revenue of WuXi Chemistry toincrease 104%/11%/30% YoY in 2022E/23E/24E, representing a 43% CAGRin FY21-24E. Cell and gene therapies (CGT) CDMO segment turned positive growth.CGT CDMO service revenue rebounded strongly to 36% YoY growth in 1H22from a 3% YoY decline in 2021, thanks to the steady increase in the numberof CGT pipeline projects, from 57 as of end-2021 to 67 as of 1H22. TheCompany’s revolutionary AAV manufacturing technology, TESSA, has gainedlarge interests from global clients. Six large biotech/pharma companies aretesting TESSA technology and one large pharma client has already initiatedTESSA technology licensure in 1H22. Given the significant yield improvement(30-40x) and cost saving (10-40x) compared with conventional productionmethod (i.e., plasmid transfection), we think TESSA has the potential tobecome a game-changer in global CGT CDMO market. Expedited globalization pace. Besides the ongoing constructions of largescale drug product manufacturing facilities in Delaware, US, WuXi AppTecannounced to further invest US$1.4bn in next 10 years to build full-suite R&Dand manufacturing capabilities in Singapore. Singapore sites will commenceoperations by 2025/26 which will enable the Company to better facilitate thegrowing and diversified client demand. Maintain BUY. We maintained our TP at RMB185.17, based on a 10-year DCFmodel (WACC: 10.94%, terminal growth rate: 3.0%).
展开>>
收起<<
《招银国际-药明康德-603259-Growth momentum to accelerate in 2H22E-220728（6页）.pdf》由会员分享，可在线阅读，更多相关《招银国际-药明康德-603259-Growth momentum to accelerate in 2H22E-220728（6页）.pdf（6页精品完整版）》请在悟空智库报告文库上搜索。
（以下内容从招银国际《Growth momentum to accelerate in 2H22E》研报附件原文摘录）药明康德(603259) Strong 1H22 results. WuXi AppTec reported 1H22 revenue of RMB17.8bn, up69% YoY (71%/66% YoY for 1Q/2Q22), attributable recurring net income ofRMB3.8bn, up 81% YoY (106%/65% YoY for 1Q/2Q22), and attributable adjustedNon-IFRS net income of RMB4.3bn, up 76% YoY (118%/49% YoY for 1Q/2Q22).Earnings are in line with our forecasts with 1H22 revenue / adjusted Non-IFRS netincome accounting for 46%/51%, respectively, of our 2022 full-year estimates.Revenue growth in 1H22 would have further accelerated by 7.2 ppts to 76% YoYand adjusted Non-IFRS GPM would have improved by 1.9 ppts YoY to 38.1%under constant currency exchange rates. The management increased its revenuegrowth guidance to 68-72% YoY from 65-70% YoY for 2022E, supported by itssolid RMB35bn backlog (+76% YoY) in 1H22. WuXi Chemistry delivered phenomenal growth despite COVID-19interruptions, driven by strong growth from both COVID and non-COVIDprojects. WuXi Chemistry revenue jumped by 102% YoY in 1H22, mainlydriven by the 145% YoY revenue growth of chemical CDMO services. Basedon our estimates, the Company booked ~RMB4.2bn revenue from commercialstage COVID-19 projects in 1H22, accounting for ~32% of WuXi Chemistryrevenue. Excluding the commercial-stage COVID-19 projects, the segmentrevenue still achieved robust growth of 37% YoY in 1H22, indicating asustainable demand from non-COVID-19 projects. Driven by the successfulone-stop CRDMO business model, we forecast revenue of WuXi Chemistry toincrease 104%/11%/30% YoY in 2022E/23E/24E, representing a 43% CAGRin FY21-24E. Cell and gene therapies (CGT) CDMO segment turned positive growth.CGT CDMO service revenue rebounded strongly to 36% YoY growth in 1H22from a 3% YoY decline in 2021, thanks to the steady increase in the numberof CGT pipeline projects, from 57 as of end-2021 to 67 as of 1H22. TheCompany’s revolutionary AAV manufacturing technology, TESSA, has gainedlarge interests from global clients. Six large biotech/pharma companies aretesting TESSA technology and one large pharma client has already initiatedTESSA technology licensure in 1H22. Given the significant yield improvement(30-40x) and cost saving (10-40x) compared with conventional productionmethod (i.e., plasmid transfection), we think TESSA has the potential tobecome a game-changer in global CGT CDMO market. Expedited globalization pace. Besides the ongoing constructions of largescale drug product manufacturing facilities in Delaware, US, WuXi AppTecannounced to further invest US$1.4bn in next 10 years to build full-suite R&Dand manufacturing capabilities in Singapore. Singapore sites will commenceoperations by 2025/26 which will enable the Company to better facilitate thegrowing and diversified client demand. Maintain BUY. We maintained our TP at RMB185.17, based on a 10-year DCFmodel (WACC: 10.94%, terminal growth rate: 3.0%).
会员中心 
开通会员